Skip to main content
PMC home page
Frontiers in Neuroscience logoLink to Frontiers in Neuroscience
. 2019 Mar 28;13:235. doi: 10.3389/fnins.2019.00235

RNA Sequencing Reveals Small and Variable Contributions of Infectious Agents to Transcriptomes of Postmortem Nervous Tissues From Amyotrophic Lateral Sclerosis, Alzheimer’s Disease and Parkinson’s Disease Subjects, and Increased Expression of Genes From Disease-Activated Microglia

James P Bennett Jr 1,2,*, Paula M Keeney 1,2, David G Brohawn 2,3,†
PMCID: PMC6447612  PMID: 30983949

Abstract

Nervous tissues from both humans with neurodegenerative diseases (NDD) and animals with genetic models of human NDD, such as rare monogenic causes of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD), show activated microglia, suggesting a potential causal role for inflammation in pathogenesis of NDD. We performed paired-end (PE) RNA sequencing (RNA seq) of total RNA’s extracted from frozen sections of cervical spinal cords from ALS and CTL subjects, frontal cortical gray matter ribbons of AD and CTL subjects, and ventral midbrains of PD and CTL subjects. Trimmed PE reads were aligned against the hg38 human transcriptome using Tophat2/Bowtie2 (ALS) or HISAT2 (AD and PD) and quantitated with Cufflinks. PE reads were also aligned using Bowtie2 against genomes from representative species of Toxoplasma gondii and Trichinella sp. T6 (parasitic infectious agents), Babesia microti and Borrelia burgdorferi (tick-vector borne agents), and Treponema denticola and Porphyromonas gingivalis, agents causing chronic gingivitis. Primary aligned reads of each agent in each tissue sample were quantitated with SAMtools. We found small percentages (<0.1%) of transcriptomes aligned with B. microti, B. burgdorferi, T. denticola, and P. gingivalis genomes and larger percentages aligned with T. gondii (0.1–0.2%) and Trichinella sp. T6 (1.0–1.1%) genomes. In AD specimens, but in no others, primary aligned transcriptome percentages, although small, approached significance for being greater in AD compared to CTL samples for B. burgdorferi (p = 0.067) and P. gingivalis (p = 0.068). Genes’ expressions in postmortem tissues of AD and ALS but not PD revealed significant changes among disease-associated microglial (DAM) genes. Infectious agents’ transcripts can be detected in RNA seq reads of both NDD and CTL tissues and vary from agent to agent. Expressions of Stage 1 and Stage 2 DAM genes significantly changed, suggesting the presence of Stages 1 and 2 DAM in our NDD tissue samples.

Keywords: neurodegeneration, microglia, ALS, Alzheimer’s disease, Parkinson’s disease, gene expression

Introduction

Microglia are CNS-resident immune cells that can serve both beneficial (reduction of immune responses) and detrimental (activation of neurotoxic immune responses) functions (all references cited are restricted to those of last 3 years, 2016–2018) (Asiimwe et al., 2016; Beamer et al., 2016; Calsolaro and Edison, 2016; Casas et al., 2016; Chen S.H. et al., 2016; Chen W.W et al., 2016; Puentes et al., 2016; Ransohoff, 2016; Rothaug et al., 2016; Su et al., 2016; Toledano et al., 2016; Trias et al., 2016; Ulrich and Holtzman, 2016; Wes et al., 2016; Au and Ma, 2017; Bagyinszky et al., 2017; Bickford et al., 2017; Blank and Prinz, 2017; Blaylock, 2017; Bolos et al., 2017; Cerami et al., 2017; Clayton et al., 2017; Collier et al., 2017; Colonna and Butovsky, 2017; Du et al., 2017; Guerriero et al., 2017; Han et al., 2017; Herz et al., 2017; Jay et al., 2017; Joers et al., 2017; Keren-Shaul et al., 2017; Kober and Brett, 2017; Koellhoffer et al., 2017; Labandeira-Garcia et al., 2017; Lall and Baloh, 2017; Lannes et al., 2017; Nissen, 2017; Plaza-Zabala et al., 2017; Roser et al., 2017; Sochocka et al., 2017; Sorce et al., 2017; Spittau, 2017; Thompson and Tsirka, 2017; Tse, 2017; van Horssen et al., 2017; Wolf et al., 2017; Yan et al., 2017; Yang et al., 2017; Aguilera et al., 2018; Baufeld et al., 2018; Bisht et al., 2018; Crisafulli et al., 2018; Deczkowska et al., 2018; Edison and Brooks, 2018; Labzin et al., 2018; Maccioni et al., 2018; Niranjan, 2018; Selles et al., 2018; Solleiro-Villavicencio and Rivas-Arancibia, 2018; Spagnuolo et al., 2018; Taylor et al., 2018).

Because activated microglia can produce known neurotoxic substances, such as tumor necrosis factor alpha (TNF-α) (Asiimwe et al., 2016; Islam, 2017; Tse, 2017), microglial presence has suggested that immune-mediated neurodegeneration may contribute to disease origin and/or progression in human neurodegenerative diseases (NDD) (op cit above).

By sorting brain immune cells and carrying out massively parallel RNA sequencing (RNA seq) on these cells over the course of disease progression in the 5X FAD mouse model of human AD Keren-Shaul et al. (2017), demonstrated the TREM2-independent (“Stage 1”) and subsequent TREM2-dependent (“Stage 2”) emergence of “disease-associated microglia,” or DAM, during clinical and pathological progression (TREM = “triggering receptor expressed on myeloid cells”).

Such DAM appeared to originate from “homeostatic” microglia (see Figure 6 in Keren-Shaul et al., 2017), then due to unknown causes, progressed to Stage 1 DAM by TREM2-independent mechanisms, followed by TREM2-mediated progression into Stage 2 DAM. At Stages 1 and 2, DAM exhibited unique genotypes, consisting mainly of up-regulated genes. Deczkowska et al. (2018) subsequently reviewed the field of DAM.

We acquired postmortem samples of CNS tissues from sporadic NDD cases and carried out moderate-high density PE RNA sequencing on total RNA to seek systems biology understandings of disease pathogenesis in ALS, AD, and PD (Bennett et al., 2016; Brohawn et al., 2016; Bennett and Keeney, 2017; Ladd et al., 2017) (see also1).

We now sought to query these data to test the hypothesis that subclinical CNS infections with common agents could be associated with microglial activation and presence of DAM. To do so, we sought (using the Bowtie2 aligner) to determine if any of the PE RNA seq reads aligned with bacteria or parasite genomes downloaded from the NIH genome site. We then assayed the expression in each NDD tissue sample (of CTL) of genes associated with homeostatic microglia, Stage 1 or Stage 2 DAM as defined by Keren-Shaul et al. (2017).

Results

In our RNA seq studies we obtained between ∼56 and ∼172 million PE reads (based on Bowtie2 alignments). From these PE reads, we found wide variation in the number of reads primarily aligned with infectious agents’ genomes. When expressed as % of total PE reads, we observed between ∼3.2 × 10-6 (B. microti) and ∼1.1 (Trichinella sp. T6). These results are summarized in Figure 1, 2, which show mean % aligned reads in each of the three NDD tissue specimens, expressed as mean ±SEM. In the case of AD frontal cortex samples, but in no others, we observed a difference between AD and CTL cases for Borrelia burgdorferi and Porphyromonas gingivalis that approached significance (p = 0.067 for B. burgdorferi and p = 0.068 for P. gingivalis, both by unpaired t-test). In no other pair did we observe a situation where NDD >CTL for transcript abundance of infectious disease agents. Because all of our total RNA extracts were treated with DNAase and used cDNA’s generated for multiplex RNA seq reads, we are confident that alignments represent NDD tissue transcripts (i.e., RNA) aligned to infectious agent genomes (i.e., DNA). We did note a substantial difference in abundance of transcripts aligned to the genome of Trichinella sp. T6 compared to all others examined.

Figure 1.

Figure 1

Open in a new tab

Bar charts of % of total PE reads that aligned in Bowtie2 to the genomes of Babesia microti, Borrelia burgdorferi, Porphyromonas gingivalis, and Treponema denticola. Shown are mean % +SD.

Figure 2.

Figure 2

Open in a new tab

Bar charts of % of total PE reads that aligned in Bowtie2 to the genomes of Toxoplasmosis gondii and Trichinella sp. T6. Shown are mean % +SD.

In the second part of our study, we examined expressions of genes associated with homeostatic microglia and Stage 1 and Stage 2 disease-associated microglia (DAM), as defined by Keren-Shaul et al. (2017); see their Figure 6) and discussed by Deczkowska et al. (2018). Figure 3 (ALS), Figure 4 (AD), and Figure 5 (PD) show the results of our RNA seq studies of gene expressions associated with (a) homeostatic microglial genes (top graph in each Figure); (b) expression of Stage 1 DAM genes (middle graph in each Figure); and (c) expression of Stage 2 DAM genes (lower graph of each Figure). Each gene’s expression is shown as % of mean CTL tissue samples expression (±SEM) for each postmortem tissue. ALS gene expressions were derived from a Tophat2/Bowtie2/Cufflinks pipeline and the AD and PD expressions were derived from a HISAT2/Cufflinks pipeline. In all cases the genes were aligned against the most current available (hg38) version of the human genome.

Figure 3.

Figure 3

Open in a new tab

Expression of genes associated with homeostatic microglia (top graph), Stage 1 DAM (middle graph), and Stage 2 DAM (bottom graph) according to Keren-Shaul et al. (2017) in ALS and CTL cervical spinal cord samples. Gene alignments were based on paired-end (PE) Illumina sequencing of rRNA-depleted tissue total RNA, followed by removal of sequencing adapters (Trimmomatic®) and alignment against the hg38 version of the human genome using Tophat2/Bowtie2 and quantitation with Cufflinks. All samples with mean CTL FPKM <2.0 were removed. Data are expressed as average ±SD of mean CTL gene expression. Two-way ANOVA results are shown in each graph. Unpaired t-tests for significance showed: (1), p = 0.055 (nearly significant); (2), p = 0.0032; (3) p = 0.040; (4), p = 0.046; (5), p = 0.0032; (6), p = 0.0018; (7), p = 0.021; (8), p = 0.0050; (9), p = 0.0038. n = 7 AlS and 8 CTL.

Figure 4.

Figure 4

Open in a new tab

Same as Figure 3, except for AD (n = 10) and CTL (n = 9) frontal cortical ribbons. Alignments against the hg38 human genome were carried out with HISAT2 and quantitated with Cufflinks. Two-way ANOVA results are given in each graph. Unpaired t-test results are as follows: (1), p = 0.014; (2), p = 0.016.

Figure 5.

Figure 5

Open in a new tab

Same as Figure 3, 4, except for PD (n = 12) and CTL (n = 8) ventral midbrain. No significant differences were detected by 2-way ANOVA or unpaired t-tests.

Two-way ANOVA tests showed significant variation by gene for the ALS (homeostatic microglial, Stages 1 and 2 DAM) and AD (homeostatic microglial and Stage 1 DAM) samples but not for the PD samples. Individual unpaired t-tests revealed significant changes for all gene groups in the ALS and two gene groups in the AD, but none for the PD samples. We note that for the Stage 1 DAM analysis in the AD samples, we found a significant decrease in expression of P2RY12 (purinergic receptor P2Y12), also observed by Keren-Shaul et al. (2017).

Discussion

By querying ∼52 to ∼172 million RNA seq paired-end (PE) reads in tissues from the three major adult NDD’s, we found that highly variable numbers of primary alignments could be found for several infectious agents known to affect humans. This is a limited list of infectious agents, and we appreciate that others could have been selected. These agents were selected based on documented infections in humans and availability of genomes. CNS involvement with parasitic infections, in particular, is known for Toxoplasma and Trichinella (Dzikowiec et al., 2017).

Our initial study of this approach yielded both very low frequencies of alignments (for B. burgdorferi, P. gingivalis, and Treponema denticola) and much higher alignment frequencies (for Trichinella sp. T6). With one exception (AD), we found no evidence that alignment frequencies in a NDD tissue set was greater than in CTL tissues from the same brain region. These findings suggest it is unlikely that sub-clinical infections could account for inflammation associated with NDD tissues we examined with RNA-seq. This assessment is tempered by the possibility that RNA species from the infectious agents could have been produced earlier in the NDD illnesses we studied, since we were restricted to CNS tissues from end-stage diseases.

By comparing expression of genes reported by Keren-Shaul et al. (2017) to be associated with homeostatic microglia, or Stage 1 or Stage 2 DAM, we observed significant changes in our AD and ALS but not PD populations. These findings suggest but do not prove that homeostatic microglia and DAM are present in our postmortem tissue samples. More stringent proof of homeostatic microglia or DAM existence would require RNA seq of individually identified microglia in each tissue sample. This approach is not feasible with our current logistical and economic constraints.

There are multiple limitations to our study. These include:

  • simple 1.

    Use of postmortem materials. RNA seq is always problematic in these tissues, likely due to variable post-mortem intervals, inevitable RNA decay during frozen sectioning, and other unknown variations. We did attempt to use comparable RNA quality specimens, but in our hands these are always less than optimal (compared, for instance, to freshly isolated cells in culture).

  • simple 2.

    End-stage disease. We do not know the effects of end-stage disease, compared to earlier stages, on any of the variables we examined. For instance, we do not know about potential loss of infectious agents’ transcripts as disease progresses, nor do we know anything about expression of DAM genes over the course of illness in humans (compared to that in mice expressing mutated NDD genes).

  • simple 3.

    Dilution of microglial gene expressions. Microglia, if present, likely represent a minority of cells. As such, their contributions to total gene expression are predicted to be limited.

  • simple 4.

    Causal relationship(s) of Stage 1/Stage 2 DAM to neurodegeneration in each NDD. We do not presume to ascribe causality of Stage 1/Stage 2 DAM presence to the neurodegenerative process represented by the subjects who donated tissues we used. This is particularly of concern since we were not able to define clearly any potential causes for NDD phenotype or DAM gene expression.

In spite of the above limitations, we hope that our findings will stimulate additional investigations into the potential role of DAM in pathogenesis of NDD’s. Lessening of DAM appearance or transition from Stage 1 DAM to Stage 2 DAM (Keren-Shaul et al., 2017) may represent a therapeutic opportunity in NDD. In addition, if our results can be extrapolated to multiple NDD’s, they suggest a common qualitative mechanism that could be therapeutically approached.

Materials and Methods

Our methods for tissue acquisition, RNA seq analyses and bioinformatics have been described in multiple publications (Bennett et al., 2016; Brohawn et al., 2016, 2018; Bennett and Keeney, 2017; Ladd et al., 2017). The particular tissue sets for ALS (Bennett et al., 2016; Brohawn et al., 2016; Ladd et al., 2017), AD (Bennett and Keeney, 2017)2 and PD (see text footnote 1) have been previously described. Briefly, tissues from persons with sporadic NDD’s were stored at -80 degrees and blocks dissected from these unfixed, frozen specimens. Frozen 20-micron tissue sections from these unfixed tissue blocks were placed into Qiazol buffer and stored at -80 degrees until RNA isolation was carried out (miRNeasy, Qiagen). An on-column DNAase step was included for each sample. RNA quality was analyzed by gel electrophoresis. Illumina sequencing libraries were constructed according to manufacturer instructions and quantitated by qPCR, either by us (ALS/CTL cervical spinal cord) or by Cofactor Genomics (AD/CTL frontal cortex, PD/CTL ventral midbrain) and paired-end (PE) Illumina sequencing was carried out by Cofactor Genomics, Inc.3 Compressed (gz) PE reads in fastq format were trimmed of Illumina sequence adapters (Trimmomatic®) and analyzed for expression based on the hg38 human genome by Tophat2/Bowtie2 (ALS) or HISAT2 (Kim et al., 2015) and quantitated with Cufflinks. In other experiments, trimmed PE reads were aligned using Bowtie2 against genomes of infectious agents, downloaded in FASTA format from the NIH website4 “genome.” Bowtie2-build was used to construct Bowtie2 index files for each genome, samtools was used to convert the SAM files to BAM files, and the samtools command samtools view -c -F 260 x.bam was used to quantitate the number of primary aligned reads in each sample for each NDD. All bioinformatics assays were performed “blind” and were based solely on sample number ID (not disease state). All graph constructions, correlations and statistical assays were performed in Prism 75.

Data Availability

All tissues were acquired commercially from National Disease Resource Interchange (http://ndriresource.org; NDRI) (ALS/CTL cervical spinal cords); under the auspices of an IRB-approved collection protocol (most AD/CTL and some PD/CTL), or were declared exempt from IRB oversight (some AD/CTL and some PD/CTL). All sequencing data discussed are the property of Neurodegeneration Therapeutics, Inc., and were acquired with private funds. Untrimmed, compressed (gz) FASTQ sequencing files are available to all legitimate investigators, following request to the corresponding author (JB), completion of a Material Transfer Agreement and provision of either a FTP URL or a memory storage device capable of storing 2 TB of data. Trimmed, processed BAM files following Trimmomatic and Tophat2/Bowtie2 analyses are also available upon reasonable request.

Author Contributions

JB, PK, and DB designed all the studies. PK oversaw the tissue acquisition and storage, and isolated and assayed the RNA’s. DB isolated the RNA’s (ALS samples), created and assayed the sequencing libraries (ALS), and performed the data analysis. JB performed all the bioinformatics assays and data analysis, and drafted the manuscript. All authors have reviewed the final manuscript and agreed with its contents.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

References

  1. Aguilera G., Colin-Gonzalez A. L., Rangel-Lopez E., Chavarria A., Santamaria A. (2018). Redox signaling, neuroinflammation, and neurodegeneration. Antioxid. Redox Signal. 28 1626–1651. 10.1089/ars.2017.7099 [DOI] [PubMed] [Google Scholar]
  2. Asiimwe N., Yeo S. G., Kim M. S., Jung J., Jeong N. Y. (2016). Nitric oxide: exploring the contextual link with alzheimer’s disease. Oxid. Med. Cell. Longev. 2016:7205747. 10.1155/2016/7205747 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Au N. P. B., Ma C. H. E. (2017). Recent advances in the study of bipolar/rod-shaped microglia and their roles in neurodegeneration. Front. Aging Neurosci. 9:128. 10.3389/fnagi.2017.00128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bagyinszky E., Giau V. V., Shim K., Suk K., An S. S. A., Kim S. (2017). Role of inflammatory molecules in the alzheimer’s disease progression and diagnosis. J. Neurol. Sci. 376 242–254. 10.1016/j.jns.2017.03.031 [DOI] [PubMed] [Google Scholar]
  5. Baufeld C., O’Loughlin E., Calcagno N., Madore C., Butovsky O. (2018). Differential contribution of microglia and monocytes in neurodegenerative diseases. J. Neural Transm. 125 809–826. 10.1007/s00702-017-1795-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Beamer E., Goloncser F., Horvath G., Beko K., Otrokocsi L., Kovanyi B., et al. (2016). Purinergic mechanisms in neuroinflammation: an update from molecules to behavior. Neuropharmacology 104 94–104. 10.1016/j.neuropharm.2015.09.019 [DOI] [PubMed] [Google Scholar]
  7. Bennett J., Keeney P. (2017). Micro RNA’s (mirna’s) may help explain expression of multiple genes in alzheimer’s frontal cortex. Journal of Systems and Integrative Neuroscience 3 1–9. 10.15761/jsin.1000178 [DOI] [Google Scholar]
  8. Bennett J. P., Jr., O’Brien L. C., Brohawn D. G. (2016). Pharmacological properties of microneurotrophin drugs developed for treatment of amyotrophic lateral sclerosis. Biochem. Pharmacol. 117 68–77. 10.1016/j.bcp.2016.08.001 [DOI] [PubMed] [Google Scholar]
  9. Bickford P. C., Flowers A., Grimmig B. (2017). Aging leads to altered microglial function that reduces brain resiliency increasing vulnerability to neurodegenerative diseases. Exp. Gerontol. 94 4–8. 10.1016/j.exger.2017.01.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bisht K., Sharma K., Tremblay M. E. (2018). Chronic stress as a risk factor for alzheimer’s disease: roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. Neurobiol. Stress 9 9–21. 10.1016/j.ynstr.2018.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Blank T., Prinz M. (2017). Type I interferon pathway in CNS homeostasis and neurological disorders. Glia 65 1397–1406. 10.1002/glia.23154 [DOI] [PubMed] [Google Scholar]
  12. Blaylock R. L. (2017). Parkinson’s disease: microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. Surg. Neurol. Int. 8:65. 10.4103/sni.sni_441_16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bolos M., Perea J. R., Avila J. (2017). Alzheimer’s disease as an inflammatory disease. Biomol. Concepts 8 37–43. 10.1515/bmc-2016-0029 [DOI] [PubMed] [Google Scholar]
  14. Brohawn D. G., Ladd A. C., O’Brien L. C., Bennett J. P., Jr. (2018). < Neuralized human embryonic or induced pluripotential stem cell-derived motor neurons are genetically different from those isolated from human adult cervical spinal cord. pdf >. J. Stem Cell Res. Med. 2 1–5. 10.15761/JSCRM.1000124 [DOI] [Google Scholar]
  15. Brohawn D. G., O’Brien L. C., Bennett J. P., Jr. (2016). RNAseq analyses identify tumor necrosis factor-mediated inflammation as a major abnormality in ALS spinal cord. PLoS One 11:e0160520. 10.1371/journal.pone.0160520 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Calsolaro V., Edison P. (2016). Neuroinflammation in alzheimer’s disease: current evidence and future directions. Alzheimers Dement 12 719–732. 10.1016/j.jalz.2016.02.010 [DOI] [PubMed] [Google Scholar]
  17. Casas C., Manzano R., Vaz R., Osta R., Brites D. (2016). Synaptic failure: focus in an integrative view of ALS. Brain Plast 1 159–175. 10.3233/BPL-140001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cerami C., Iaccarino L., Perani D. (2017). Molecular imaging of neuroinflammation in neurodegenerative dementias: the role of in vivo PET imaging. Int. J. Mol. Sci. 18:993. 10.3390/ijms18050993 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chen S. H., Oyarzabal E. A., Hong J. S. (2016). Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegeneration. Curr. Opin. Pharmacol. 26 54–60. 10.1016/j.coph.2015.10.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Chen W. W., Zhang X., Huang W. J. (2016). Role of neuroinflammation in neurodegenerative diseases (Review). Mol. Med. Rep. 13 3391–3396. 10.3892/mmr.2016.4948 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Clayton K. A., Van Enoo A. A., Ikezu T. (2017). Alzheimer’s disease: the role of microglia in brain homeostasis and proteopathy. Front. Neurosci. 11:680 10.3389/fnins.2017.00680 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Collier T. J., Kanaan N. M., Kordower J. H. (2017). Aging and parkinson’s disease: different sides of the same coin? Mov. Disord. 32 983–990. 10.1002/mds.27037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Colonna M., Butovsky O. (2017). Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 35 441–468. 10.1146/annurev-immunol-051116-052358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Crisafulli S. G., Brajkovic S., Cipolat Mis M. S., Parente V., Corti S. (2018). Therapeutic strategies under development targeting inflammatory mechanisms in amyotrophic lateral sclerosis. Mol. Neurobiol. 55 2789–2813. 10.1007/s12035-017-0532-4 [DOI] [PubMed] [Google Scholar]
  25. Deczkowska A., Keren-Shaul H., Weiner A., Colonna M., Schwartz M., Amit I. (2018). Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173 1073–1081. 10.1016/j.cell.2018.05.003 [DOI] [PubMed] [Google Scholar]
  26. Du L., Zhang Y., Chen Y., Zhu J., Yang Y., Zhang H. L. (2017). Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol. Neurobiol. 54 7567–7584. 10.1007/s12035-016-0245-0 [DOI] [PubMed] [Google Scholar]
  27. Dzikowiec M., Goralska K., Blaszkowska J. (2017). Neuroinvasions caused by parasites. Ann. Parasitol. 63 243–253. 10.17420/ap6304.111 [DOI] [PubMed] [Google Scholar]
  28. Edison P., Brooks D. J. (2018). Role of neuroinflammation in the trajectory of alzheimer’s disease and in vivo quantification using PET. J. Alzheimers Dis. 64 S339–S351. 10.3233/JAD-179929 [DOI] [PubMed] [Google Scholar]
  29. Guerriero F., Sgarlata C., Francis M., Maurizi N., Faragli A., Perna S., et al. (2017). Neuroinflammation, immune system and alzheimer disease: searching for the missing link. Aging Clin. Exp. Res. 29 821–831. 10.1007/s40520-016-0637-z [DOI] [PubMed] [Google Scholar]
  30. Han J., Wang M., Ren M., Lou H. (2017). Contributions of triggering-receptor-expressed-on-myeloid-cells-2 to neurological diseases. Int. J. Neurosci. 127 368–375. 10.1080/00207454.2016.1264072 [DOI] [PubMed] [Google Scholar]
  31. Herz J., Filiano A. J., Smith A., Yogev N., Kipnis J. (2017). Myeloid cells in the central nervous system. Immunity 46 943–956. 10.1016/j.immuni.2017.06.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Islam M. T. (2017). Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol. Res. 39 73–82. 10.1080/01616412.2016.1251711 [DOI] [PubMed] [Google Scholar]
  33. Jay T. R., von Saucken V. E., Landreth G. E. (2017). TREM2 in neurodegenerative diseases. Mol. Neurodegener. 12:56. 10.1186/s13024-017-0197-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Joers V., Tansey M. G., Mulas G., Carta A. R. (2017). Microglial phenotypes in Parkinson’s disease and animal models of the disease. Prog. Neurobiol. 155 57–75. 10.1016/j.pneurobio.2016.04.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T. K., et al. (2017). A unique microglia type associated with restricting development of alzheimer’s disease. Cell 169:1276-1290.e17. 10.1016/j.cell.2017.05.018 [DOI] [PubMed] [Google Scholar]
  36. Kim D., Langmead B., Salzberg S. L. (2015). HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12 357–360. 10.1038/nmeth.3317 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Kober D. L., Brett T. J. (2017). TREM2-ligand interactions in health and disease. J. Mol. Biol. 429 1607–1629. 10.1016/j.jmb.2017.04.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Koellhoffer E. C., McCullough L. D., Ritzel R. M. (2017). Old maids: aging and its impact on microglia function. Int. J. Mol. Sci. 18:769. 10.3390/ijms18040769 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Labandeira-Garcia J. L., Rodriguez-Perez A. I., Garrido-Gil P., Rodriguez-Pallares J., Lanciego J. L., Guerra M. J. (2017). Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration. Front. Aging Neurosci. 9:129. 10.3389/fnagi.2017.00129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Labzin L. I., Heneka M. T., Latz E. (2018). Innate immunity and neurodegeneration. Annu. Rev. Med. 69 437–449. 10.1146/annurev-med-050715-104343 [DOI] [PubMed] [Google Scholar]
  41. Ladd A. C., Brohawn D. G., Thomas R. R., Keeney P. M., Berr S. S., Khan S. M., et al. (2017). RNA-seq analyses reveal that cervical spinal cords and anterior motor neurons from amyotrophic lateral sclerosis subjects show reduced expression of mitochondrial DNA-encoded respiratory genes, and rhTFAM may correct this respiratory deficiency. Brain Res. 1667 74–83. 10.1016/j.brainres.2017.05.010 [DOI] [PubMed] [Google Scholar]
  42. Lall D., Baloh R. H. (2017). Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Invest. 127 3250–3258. 10.1172/JCI90607 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Lannes N., Eppler E., Etemad S., Yotovski P., Filgueira L. (2017). Microglia at center stage: a comprehensive review about the versatile and unique residential macrophages of the central nervous system. Oncotarget 8 114393–114413. 10.18632/oncotarget.23106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Maccioni R. B., Gonzalez A., Andrade V., Cortes N., Tapia J. P., Guzman-Martinez L. (2018). Alzheimer s disease in the perspective of neuroimmunology. Open Neurol. J. 12 50–56. 10.2174/1874205X01812010050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Niranjan R. (2018). Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration. Neurochem. Int. 120 13–20. 10.1016/j.neuint.2018.07.003 [DOI] [PubMed] [Google Scholar]
  46. Nissen J. C. (2017). Microglial function across the spectrum of age and gender. Int. J. Mol. Sci. 18:561. 10.3390/ijms18030561 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Plaza-Zabala A., Sierra-Torre V., Sierra A. (2017). Autophagy and microglia: novel partners in neurodegeneration and aging. Int. J. Mol. Sci. 18:598. 10.3390/ijms18030598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Puentes F., Malaspina A., van Noort J. M., Amor S. (2016). Non-neuronal cells in ALS: role of glial, immune cells and blood-CNS barriers. Brain Pathol. 26 248–257. 10.1111/bpa.12352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Ransohoff R. M. (2016). How neuroinflammation contributes to neurodegeneration. Science 353 777–783. 10.1126/science.aag2590 [DOI] [PubMed] [Google Scholar]
  50. Roser A. E., Tonges L., Lingor P. (2017). Modulation of microglial activity by Rho-Kinase (ROCK) inhibition as therapeutic strategy in parkinson’s disease and amyotrophic lateral sclerosis. Front. Aging Neurosci. 9:94 10.3389/fnagi.2017.00094 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Rothaug M., Becker-Pauly C., Rose-John S. (2016). The role of interleukin-6 signaling in nervous tissue. Biochim. Biophys. Acta 1863(6 Pt A), 1218–1227. 10.1016/j.bbamcr.2016.03.018 [DOI] [PubMed] [Google Scholar]
  52. Selles M. C., Oliveira M. M., Ferreira S. T. (2018). Brain inflammation connects cognitive and non-cognitive symptoms in alzheimer’s disease. J. Alzheimers Dis. 64 S313–S327. 10.3233/JAD-179925 [DOI] [PubMed] [Google Scholar]
  53. Sochocka M., Diniz B. S., Leszek J. (2017). Inflammatory response in the CNS: friend or foe? Mol. Neurobiol. 54 8071–8089. 10.1007/s12035-016-0297-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Solleiro-Villavicencio H., Rivas-Arancibia S. (2018). Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4(+)T cells in neurodegenerative diseases. Front. Cell Neurosci. 12:114. 10.3389/fncel.2018.00114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Sorce S., Stocker R., Seredenina T., Holmdahl R., Aguzzi A., Chio A., et al. (2017). NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: what is the evidence? Free Radic Biol. Med. 112 387–396. 10.1016/j.freeradbiomed.2017.08.006 [DOI] [PubMed] [Google Scholar]
  56. Spagnuolo C., Moccia S., Russo G. L. (2018). Anti-inflammatory effects of flavonoids in neurodegenerative disorders. Eur. J. Med. Chem. 153 105–115. 10.1016/j.ejmech.2017.09.001 [DOI] [PubMed] [Google Scholar]
  57. Spittau B. (2017). Aging microglia-phenotypes, functions and implications for age-related neurodegenerative diseases. Front. Aging Neurosci. 9:194. 10.3389/fnagi.2017.00194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Su W., Aloi M. S., Garden G. A. (2016). MicroRNAs mediating CNS inflammation: small regulators with powerful potential. Brain Behav. Immun. 52 1–8. 10.1016/j.bbi.2015.07.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Taylor J. M., Moore Z., Minter M. R., Crack P. J. (2018). Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on alzheimer’s disease. J. Neural Transm. 125 797–807. 10.1007/s00702-017-1745-4 [DOI] [PubMed] [Google Scholar]
  60. Thompson K. K., Tsirka S. E. (2017). The diverse roles of microglia in the neurodegenerative aspects of Central Nervous System (CNS) autoimmunity. Int. J. Mol. Sci. 18:504. 10.3390/ijms18030504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Toledano A., Alvarez M. I., Toledano-Diaz A., Merino J. J., Rodriguez J. J. (2016). Brain local and regional neuroglial alterations in alzheimer’s disease: cell types, responses and implications. Curr. Alzheimer Res. 13 321–342. 10.2174/1567205013666151116141217 [DOI] [PubMed] [Google Scholar]
  62. Trias E., Ibarburu S., Barreto-Nunez R., Babdor J., Maciel T. T., Guillo M., et al. (2016). Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflamm. 13:177. 10.1186/s12974-016-0620-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Tse J. K. Y. (2017). Gut microbiota, nitric oxide, and microglia as prerequisites for neurodegenerative disorders. ACS Chem. Neurosci. 8 1438–1447. 10.1021/acschemneuro.7b00176 [DOI] [PubMed] [Google Scholar]
  64. Ulrich J. D., Holtzman D. M. (2016). TREM2 function in alzheimer’s disease and neurodegeneration. ACS Chem. Neurosci. 7 420–427. 10.1021/acschemneuro.5b00313 [DOI] [PubMed] [Google Scholar]
  65. van Horssen J., van Schaik P., Witte M. (2017). Inflammation and mitochondrial dysfunction: a vicious circle in neurodegenerative disorders? Neurosci. Lett. 10.1016/j.neulet.2017.06.050 [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  66. Wes P. D., Sayed F. A., Bard F., Gan L. (2016). Targeting microglia for the treatment of alzheimer’s disease. Glia 64 1710–1732. 10.1002/glia.22988 [DOI] [PubMed] [Google Scholar]
  67. Wolf S. A., Boddeke H. W., Kettenmann H. (2017). Microglia in physiology and disease. Annu. Rev. Physiol. 79 619–643. 10.1146/annurev-physiol-022516-034406 [DOI] [PubMed] [Google Scholar]
  68. Yan Q., Han C., Wang G., Waddington J. L., Zheng L., Zhen X. (2017). Activation of AMPK/mTORC1-mediated autophagy by metformin reverses Clk1 deficiency-sensitized dopaminergic neuronal death. Mol. Pharmacol. 92 640–652. 10.1124/mol.117.109512 [DOI] [PubMed] [Google Scholar]
  69. Yang H. M., Yang S., Huang S. S., Tang B. S., Guo J. F. (2017). Microglial activation in the pathogenesis of huntington’s disease. Front. Aging Neurosci. 9:193 10.3389/fnagi.2017.00193 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All tissues were acquired commercially from National Disease Resource Interchange (http://ndriresource.org; NDRI) (ALS/CTL cervical spinal cords); under the auspices of an IRB-approved collection protocol (most AD/CTL and some PD/CTL), or were declared exempt from IRB oversight (some AD/CTL and some PD/CTL). All sequencing data discussed are the property of Neurodegeneration Therapeutics, Inc., and were acquired with private funds. Untrimmed, compressed (gz) FASTQ sequencing files are available to all legitimate investigators, following request to the corresponding author (JB), completion of a Material Transfer Agreement and provision of either a FTP URL or a memory storage device capable of storing 2 TB of data. Trimmed, processed BAM files following Trimmomatic and Tophat2/Bowtie2 analyses are also available upon reasonable request.

Articles from Frontiers in Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES